Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
38,466,645
-
Number of holders
-
29
-
Total 13F shares, excl. options
-
5,478,113
-
Shares change
-
-178,980
-
Total reported value, excl. options
-
$14,679,319
-
Value change
-
-$481,979
-
Put/Call ratio
-
88%
-
Number of buys
-
8
-
Number of sells
-
-11
-
Price
-
$2.68
Significant Holders of Protara Therapeutics, Inc. - Common Stock (TARA) as of Q4 2022
32 filings reported holding TARA - Protara Therapeutics, Inc. - Common Stock as of Q4 2022.
Protara Therapeutics, Inc. - Common Stock (TARA) has 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5,478,113 shares
of 38,466,645 outstanding shares and own 14% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (2,692,594 shares), ORBIMED ADVISORS LLC (830,641 shares), VANGUARD GROUP INC (427,612 shares), PERCEPTIVE ADVISORS LLC (290,051 shares), Boxer Capital, LLC (209,227 shares), BAKER BROS. ADVISORS LP (199,671 shares), Ikarian Capital, LLC (188,664 shares), Privium Fund Management (UK) Ltd (119,730 shares), GEODE CAPITAL MANAGEMENT, LLC (83,420 shares), and RENAISSANCE TECHNOLOGIES LLC (67,000 shares).
This table shows the top 29 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.